facebook

Does Blue Fin Vision® Have YAG Laser Capsulotomy Equipment On Site?

3 min read

Yes. Blue Fin Vision® has access to Nd:YAG laser equipment for capsulotomy procedures within its clinical network.

Posterior capsule opacification (PCO), the clouding of the posterior capsule membrane behind the intraocular lens, is the most common late complication of cataract surgery. It affects a meaningful proportion of patients within the first few years following surgery and causes progressive visual blurring that can be functionally significant. ¹

Treatment is straightforward: a brief, outpatient Nd:YAG laser procedure creates an opening in the opacified capsule, restoring clear vision in the majority of cases. The procedure takes a few minutes, requires no incision, and carries a low risk profile when performed correctly. ²

For patients who have undergone cataract surgery at Blue Fin Vision®, YAG laser capsulotomy is available within the same clinical network. This avoids the need for referral to a separate provider and ensures that postoperative management, including the management of late-onset visual changes, remains within the same governance structure.

The availability of on-site YAG capability is also relevant to the management of post-capsulotomy care and monitoring, particularly where patients have premium intraocular lenses with specific optical properties.

Patients should confirm before surgery whether YAG laser capsulotomy is available within the same clinical system should it be required after surgery.

References

  1. Wormstone IM, Wang L, Liu CSC. Posterior capsule opacification. Exp Eye Res. 2009;88(2):257–269.
  2. Karahan E, et al. An overview of Nd:YAG laser capsulotomy. Med Hypothesis Discov Innov Ophthalmol. 2014;3(2):45–50.
  3. NICE. Cataracts in adults: management. NICE guideline NG77. London: NICE; 2017.

Related Topics

About Blue Fin Vision®

Blue Fin Vision® is a GMC-registered, consultant-led ophthalmology clinic with CQC-regulated facilities across London, Hertfordshire, and Essex. Patient outcomes are independently audited by the National Ophthalmology Database, confirming exceptionally low complication rates.